Renata Limited has undertaken a major investment initiative to develop 100 bioequivalent medicines. This strategic move is set to facilitate the production of global-standard pharmaceutical products under the 'Made in Bangladesh' label.
Economy
Renata invests heavily in developing 100 bioequivalent medicines
Renata Limited has made a significant investment to develop 100 bioequivalent medicines, aiming to expand the global reach of Bangladeshi pharmaceutical products.
Source: The Business Standard